Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.71 |
| ▸ | CA2 | P00918 | 6/20 | 0.71 |
| ▸ | CA12 | O43570 | 5/20 | 0.71 |
| ▸ | CA7 | P43166 | 5/20 | 0.71 |
| ▸ | CA9 | Q16790 | 5/20 | 0.71 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.71 |
| ▸ | XDH | P47989 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10421921 | 0.89 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL10420353 | 0.88 | CA12 (0.57) | CA1CA2CA12CA7CA9 | |
| SCHEMBL10420343 | 0.87 | CA12 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL31156266 | 0.87 | CA1 (0.65) | CA1CA2CA12CA7CA9 | |
| SCHEMBL498118 | 0.85 | ERN1 (0.65) | CA1CA2CA12CA7CA9 | |
| SCHEMBL197972 | 0.84 | CA1 (0.71) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30809635 | 0.84 | CA1 (0.71) | CA1CA2CA12CA7CA9 | |
| Methyl Protocatechuate SCHEMBL38624 | 0.83 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| Methyl Protocatechuate SCHEMBL29360855 | 0.83 | CA1 (1.00) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30029511 | 0.83 | MAPT (0.63) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113748021-B | Method for producing liquid crystal polyester processed product | 本州化学工业株式会社 | 2024-07-05 | — | — | CN | claimed |
| CN-110093064-B | Preparation method and application of long-afterglow luminescent ink | 重庆理工大学 | 2021-07-13 | — | — | CN | claimed |
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4702026-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4633683-A1 | CYCLOOCTENE COMPOSITIONS AND USES THEREOF | Biogen MA Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12421452-B2 | Method for producing liquid-crystal polyester processed product | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | disclosed |
| EP-4561975-A1 | FTO INHIBITORS | RPXDS Co., Ltd (CN) | 2025-06-04 | — | — | EP | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-119546566-A | FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-4939267-A | Viricides | STERLING DRUG INC. (US) | 1990-07-03 | — | — | US | disclosed |
| US-4937281-A | ACRYLIC BINDER OF ALKYL ACRYLATES HAVING PENDANT AMINOESTERS OR HYDROXYAMINO ESTER GROUPS, SOLVENT AND AN ALKYL P-HYDROXY BENZOATE AS CURING CATALYST; AUTO REFINISHES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-06-26 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4895768-A | CROSSLINKED ACRYLIC ESTER | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-01-23 | — | — | US | disclosed |
| US-4843087-A | OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES | STERLING DRUG INC. (US) | 1989-06-27 | — | — | US | disclosed |
| EP-0137242-A2 | (Substituted) Phenyl-aliphatic-isoxazoles useful as antiviral agents and preparation thereof | STERLING WINTHROP INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4138579-A | INSECTICIDES | HOFFMANN-LA ROCHE INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4051319-A | INSECTICIDES | HOFFMANN-LA ROCHE INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-3957833-A | KILLING INSECTS, HORMONES | HOFFMANN-LA ROCHE INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | CA1 789/4885CA2 187/4885CA12 75/4885 |
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | CA1 3210/4885CA2 3929/4885CA12 4386/4885 |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CA1 4855/4885CA2 4707/4885CA12 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.